BiotechTube

enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostate Cancer

Conditions

Prostate Cancer

Trial Timeline

Dec 22, 2016 → Jul 31, 2029

NCT ID
NCT02960022

About enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate

enzalutamide + abiraterone acetate + prednisone + Leuprolide acetate is a phase 2 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02960022. Target conditions include Prostate Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Prostate Cancer were approved

Approved (20) Terminated (4) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved
✅LeuprolideAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02960022Phase 2Recruiting

Competing Products

20 competing products in Prostate Cancer

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
18
PemetrexedEli LillyPhase 2
35
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
Abemaciclib + Placebo + Abiraterone acetate + PrednisoneEli LillyPhase 2/3
42
eFT508eFFECTOR TherapeuticsPhase 2
17
EnhertuDaiichi SankyoPhase 2
42
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
47
exatecan mesylateDaiichi SankyoPhase 2
35
PLX3397Daiichi SankyoPhase 2
27
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
29
degarelix + GoserelinAstellas PharmaPhase 3
40
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
26
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
YM155Astellas PharmaPhase 2
35